



AAT Deficiency

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process.** If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: _____ Date: _____
Patient's ID: _____ Patient's Date of Birth: _____
Physician's Name: _____
Specialty: _____ NPI#: _____
Physician Office Telephone: _____ Physician Office Fax: _____

Referring Provider Info: Same as Requesting Provider

Name: _____ NPI#: _____
Fax: _____ Phone: _____

Rendering Provider Info: Same as Referring Provider Same as Requesting Provider

Name: _____ NPI#: _____
Fax: _____ Phone: _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____ kg
Patient Height: _____ cm

Drug Information:

Strength/Measure _____ Units ml Gm mg ea Un
Directions(sig) _____ Route of administration _____
Dosing frequency _____

Site of Service Questions:

- A. Indicate the site of service requested:
 On Campus Outpatient Hospital Off Campus Outpatient Hospital
 Home based setting, *skip to Criteria Questions* Community office, *skip to Criteria Questions*
 Ambulatory infusion site, *skip to Criteria Questions*
- B. Is the patient less than 18 years of age?
 Yes, *skip to Clinical Criteria Questions*
 No
- C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC AAT Deficiency SGM 1877-A – 07/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076
Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com

- seizures) during or immediately after an infusion? **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.** Yes, skip to Clinical Criteria Questions No
- D. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.**
 Yes, skip to Clinical Criteria Questions No
- E. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.**
 Yes, skip to Clinical Criteria Questions No
- F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.**
 Yes, skip to Clinical Criteria Questions No
- G. Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.**
 Yes, skip to Clinical Criteria Questions No
- H. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?
ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation. Yes No

Clinical Criteria Questions:

1. What drug is being prescribed? Aralast NP Glassia Prolastin-C Zemaira Other _____
2. What is the diagnosis?
 Alpha₁-antitrypsin (AAT) deficiency (also known as alpha₁-proteinase inhibitor deficiency)
 Other (please specify) _____
3. What is the ICD-10 code? _____
4. Does the patient have emphysema due to alpha₁-antitrypsin (AAT) deficiency? Yes No
5. Is this a request for continuation of therapy with the requested drug? Yes No *If No, skip to #8*
6. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? Yes No Unknown *If Yes or Unknown skip to #8*
7. Is the patient experiencing beneficial clinical response from therapy? Yes No *No further questions*
8. Is the patient's pretreatment post-bronchodilation FEV₁ (forced expiratory volume in 1 second) greater than or equal to 25 percent and less than or equal to 80 percent of the predicted value? **ACTION REQUIRED: If Yes, attach supporting test results.** Yes No
9. What is the patient's pretreatment serum alpha₁-antitrypsin (AAT) level? **ACTION REQUIRED: If Yes, attach supporting test results.** _____ micromol/L OR mg/dL (*circle units*) No serum AAT level
10. Has testing been done to establish the patient's alpha₁-antitrypsin protein phenotype or genotype? **ACTION REQUIRED: If Yes, attach alpha₁-antitrypsin phenotyping test result.** Yes No
11. What is the patient's alpha₁-antitrypsin protein phenotype?

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC AAT Deficiency SGM 1877-A – 07/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com

- PiZZ
- PiZ (null)
- Pi (null, null)
- PiMZ
- PiMS
- Other phenotype or genotype associated with serum AAT concentrations of less than 11 micromol/L (80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry)
- Unknown

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC AAT Deficiency SGM 1877-A – 07/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com